Relay Therapeutics, a clinical-stage biopharmaceutical firm, relies on its Dynamo® drug discovery platform to develop novel therapies. Despite technology progress, the company remains unprofitable with no approved products and reported $15.4 million in revenue in 2025 primarily from collaborations. Operating losses narrowed modestly year-over-year but remain substantial. The company faces risks including clinical trial uncertainties, regulatory complexities, supply chain dependencies, intellectual property challenges, and ongoing capital needs.